Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN Z versus YUVIWEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN Z versus YUVIWEL.
TRAVATAN Z vs YUVIWEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by binding to FP receptors in the ciliary muscle and trabecular meshwork, leading to matrix metalloproteinase activation and remodeling of extracellular matrix.
YUVIWEL (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces the uptake of monoamines (such as dopamine) into synaptic vesicles, thereby decreasing their release into the synaptic cleft, which reduces dopaminergic transmission implicated in hyperkinetic movement disorders.
One drop in the affected eye(s) once daily in the evening. Ophthalmic solution 0.004% (travoprost 0.04 mg/mL).
No established standard dosing for YUVIWEL; drug not recognized.
None Documented
None Documented
Terminal elimination half-life is 45 minutes; due to rapid hydrolysis to active acid, the clinical effect duration is longer than the half-life suggests.
Terminal elimination half-life is 12 hours; steady-state reached within 48-60 hours, requiring dose adjustment in renal impairment.
Primarily eliminated via hepatic metabolism; renal excretion of metabolites accounts for approximately 20% of the dose; fecal excretion is minimal.
Renal excretion of unchanged drug accounts for 70% of clearance; biliary/fecal elimination constitutes 30%.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog